SuJok Therapy For The Treatment Of Type 2 Diabetes
SuJok Therapy For The Treatment Of Type 2 Diabetes
DOI:
https://doi.org/10.70284/njirm.v12i6.3283Keywords:
Sujok For Diabetes Mellitus, TIID, Diabetes Treatment, HbA1c, RPG, Random Plasma Glucose, Glycated Hemoglobin, Sujok Therapy, Seed Therapy, CorrespondenceAbstract
Background: Diabetes mellitus is one of the oldest characterized diseases in the world. By today diabetes has become a worldwide epidemic that is associated with the modern lifestyle, increased stress, improper nutrition or eating behaviours and lack of physical activity. Material And Methods: 330 patients aged 30-76 years were administered to the study. All the metabolic marker analyses were conducted using an automated clinical chemistry analyzer (Dimension Xpand Plus, Siemens Healthcare, Germany). Random Plasma glucose levels (RPG) was taken 2-4 hours post meal. Sujok treatments were carried out by certified Sujok Therapists according to the Diabetes treatment protocol (ISA R&D center, Nagpur, India). Result: A major decrease in plasma glucose levels was recorded 30 minutes after the initial Sujok treatment. Following 5 treatments, 70% of the patients responded in decrease in glucose levels (52.45±10.49 mg/dl) while 24% increase in glucose levels (22.2±7.4 mg/dl), 6% of the patients did not show any change in glucose plasma levels. HbA1c was monitored in the patients that undergone 3 months of Sujok treatment. A considerable decrease in the percent of HbA1c was observed in the plasma of treated patients (5.53±0.98%), in comparison to the initial level measured prior to the treatment procedure (8.13±1.29%). Conclusion: This study is a pilot study to evaluate possible effect of Sujok therapy for the treatment of diabetes. Overall, it seems that Sujok therapy may decrease glucose levels and HbA1c levels. These results can support the efforts to develop improved therapeutic and preventive strategies for diabetes. A following research regarding the treatment of diabetes complications by Sujok therapy is currently running with promising results. [Yagil Z Natl J Integr Res Med, 2021; 12(6): 81-87]